Globular glial tauopathy caused by MAPT P301T mutation: clinical and neuropathological findings.

Corticobasal degeneration Frontotemporal dementia Genetic linkage Globular glial tauopathy Progressive supranuclear palsy Protein tau

Journal

Journal of neurology
ISSN: 1432-1459
Titre abrégé: J Neurol
Pays: Germany
ID NLM: 0423161

Informations de publication

Date de publication:
Oct 2019
Historique:
received: 14 03 2019
accepted: 31 05 2019
revised: 30 05 2019
pubmed: 14 6 2019
medline: 26 2 2020
entrez: 14 6 2019
Statut: ppublish

Résumé

To describe the clinical, biochemical, and neuropathological findings of an autosomal dominant globular glial tauopathy caused by the P301T mutation at the MAPT gene. Five patients from two unrelated pedigrees underwent clinical evaluation. Genetic analysis, brain pathological examination, and biochemical analysis of tau were performed. The patients studied were 3 men and 2 women with a mean age at onset of 52.2 years and mean disease duration of 5.2 years. Three patients presented a corticobasal syndrome, one patient an asymmetric pyramidal syndrome compatible with primary lateral sclerosis, and one patient a frontotemporal dementia. In both pedigrees (4 patients) Sanger sequencing showed the p.P301T mutation in exon 10 of the MAPT gene. Neuropathological findings consisted of atrophy of frontal and temporal lobes with marked spongiosis and astrogliosis, and abundant phosphorylated tau protein deposits in the frontal and temporal cortex, limbic area, basal ganglia, and brain stem. The most striking finding was the presence of oligodendroglial 4R phospho-tau globular positive inclusions in the white matter and cortex. Globose-type neurofibrillary neuronal tangles, and in particular astrocytic globular inclusions and coarse tufts, were present in the grey matter. Biochemical analysis of sarkosyl-insoluble fractions revealed two tau bands of 64 and 68 kDa and case-dependent bands of lower molecular weight. This is the first pathological and biochemical study of the MAPT p.P301T mutation showing variable clinical manifestation and neuropathological phenotype of globular glial tauopathy not only among different families but also within families.

Identifiants

pubmed: 31190169
doi: 10.1007/s00415-019-09414-w
pii: 10.1007/s00415-019-09414-w
doi:

Substances chimiques

MAPT protein, human 0
tau Proteins 0

Types de publication

Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2396-2405

Références

Brain. 2018 Feb 1;141(2):521-534
pubmed: 29253099
Acta Neuropathol. 2005 Dec;110(6):600-9
pubmed: 16328530
Eur J Neurol. 2007 Aug;14(8):e9-10
pubmed: 17662000
Acta Neuropathol. 2001 Sep;102(3):285-92
pubmed: 11585254
Acta Neuropathol. 2003 Nov;106(5):419-35
pubmed: 12955398
Ann Neurol. 2002 Apr;51(4):525-30
pubmed: 11921059
Acta Neuropathol. 2005 Mar;109(3):329-38
pubmed: 15841415
Neuropathol Appl Neurobiol. 2017 Apr;43(3):200-214
pubmed: 27859539
Acta Neuropathol. 2015 Aug;130(2):199-214
pubmed: 25900293
J Neuropathol Exp Neurol. 2008 Oct;67(10):963-75
pubmed: 18800011
Eur Neurol. 1998 Aug;40(2):71-7
pubmed: 9693235
Acta Neuropathol. 2011 Oct;122(4):415-28
pubmed: 21773886
Acta Neuropathol. 2003 Aug;106(2):181-7
pubmed: 12783250
Alzheimers Dement (Amst). 2016 Apr 08;4:6-13
pubmed: 27489873
Neurology. 2005 May 10;64(9):1578-85
pubmed: 15883319
J Neuropathol Exp Neurol. 2001 Apr;60(4):328-41
pubmed: 11305868
Prog Neurobiol. 2018 Oct;169:24-54
pubmed: 30077775
Acta Neuropathol. 2013 Oct;126(4):537-544
pubmed: 23995422
Dement Geriatr Cogn Disord. 2017;44(3-4):213-221
pubmed: 28934750
Acta Neuropathol. 2010 Jul;120(1):21-32
pubmed: 20140439
J Neuropathol Exp Neurol. 2006 Apr;65(4):396-405
pubmed: 16691120

Auteurs

M E Erro (ME)

Neurology Department, Complejo Hospitalario de Navarra, C/Irunlarrea 3, 31008, Pamplona, Navarra, Spain. elena.erro.aguirre@cfnavarra.es.
Neuroepigenetics Laboratory-Navarrabiomed, Complejo Hospitalario de Navarra, Universidad Pública de Navarra (UPNA), IdiSNA (Navarra Institute for Health Research), Pamplona, Spain. elena.erro.aguirre@cfnavarra.es.

M V Zelaya (MV)

Pathology Department, Complejo Hospitalario de Navarra, Pamplona, Spain.
Brain Bank, Navarrabiomed, IdiSNA (Navarra Institute for Health Research), Pamplona, Spain.

M Mendioroz (M)

Neurology Department, Complejo Hospitalario de Navarra, C/Irunlarrea 3, 31008, Pamplona, Navarra, Spain.
Neuroepigenetics Laboratory-Navarrabiomed, Complejo Hospitalario de Navarra, Universidad Pública de Navarra (UPNA), IdiSNA (Navarra Institute for Health Research), Pamplona, Spain.

R Larumbe (R)

Neurology Department, Complejo Hospitalario de Navarra, C/Irunlarrea 3, 31008, Pamplona, Navarra, Spain.
Neuroepigenetics Laboratory-Navarrabiomed, Complejo Hospitalario de Navarra, Universidad Pública de Navarra (UPNA), IdiSNA (Navarra Institute for Health Research), Pamplona, Spain.

S Ortega-Cubero (S)

Neurosurgery and Neurology Department, Hospital Universitario de Burgos, Burgos, Spain.

J L Lanciego (JL)

Neurosciences Department, Center for Applied Medical Research (CIMA), IdiSNA (Navarra Institute for Health Research), Pamplona, Spain.
Biomedical Network Research Centre of Neurodegenerative Diseases (CIBERNED), Madrid, Spain.

A Lladó (A)

Alzheimer's Disease and Other Cognitive Disorders Unit. Neurology Department, IDIBAPS. Hospital Clínic, Barcelona, Spain.

T Cabada (T)

Neuroepigenetics Laboratory-Navarrabiomed, Complejo Hospitalario de Navarra, Universidad Pública de Navarra (UPNA), IdiSNA (Navarra Institute for Health Research), Pamplona, Spain.
Neuroradiology Department, Complejo Hospitalario de Navarra, Pamplona, Spain.

T Tuñón (T)

Pathology Department, Complejo Hospitalario de Navarra, Pamplona, Spain.
Brain Bank, Navarrabiomed, IdiSNA (Navarra Institute for Health Research), Pamplona, Spain.

F García-Bragado (F)

Pathology Department, Complejo Hospitalario de Navarra, Pamplona, Spain.
Brain Bank, Navarrabiomed, IdiSNA (Navarra Institute for Health Research), Pamplona, Spain.

M R Luquin (MR)

Neurology Department, Clínica Universidad de Navarra, IdiSNA (Navarra Institute for Health Research), Pamplona, Spain.

P Pastor (P)

Movement Disorders Unit, Neurology Department, Hospital Universitari Mutua de Terrassa, University of Barcelona School of Medicine and Fundació per la Recerca Biomèdica i Social Mútua Terrassa, Terrassa, Barcelona, Spain.

I Ferrer (I)

Biomedical Network Research Centre of Neurodegenerative Diseases (CIBERNED), Madrid, Spain.
University of Barcelona, Bellvitge University Hospital-IDIBELL, Hospitalet de Llobregat, Hospitalet de Llobregat, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH